MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/03331024261478621

Медицинская библиотека · Cephalalgia : an international journal of headache · 2026

Development and external validation of a migraine analgesic usage (MAU) index for identifying high-severity migraine: A multi-center study.

Li Hui, Xu Xiaonuo, Che Linyi, Fan Xiaoping, Tan Ge, Ma Jingxi, Pan Qi, Hong Peiwei, Zhong Chengqing, Li Jiao, Chen Xiaorong, Dong Liang, Zhou Jiying

СтатьяМногоцентровое исследованиеВалидационное исследованиеПеревод в очереди

Аннотация

AimTo determine whether a two-variable scorecard combining monthly acute medication days and the six-item Migraine Treatment Optimization Questionnaire can identify high multidimensional migraine burden, defined operationally as a four-domain composite (monthly migraine days, acute medication days, pain intensity, and disability) score ≥50 (range 0-100), with sufficient discrimination and clinical utility for bedside triage.MethodsWe performed a cross-sectional analysis of baseline data from a multicenter, prospective, real-world migraine registry in China (enrolment January 2024 - December 2025). Adults with migraine and complete data for the four-domain composite and the six-item Migraine Treatment Optimization Questionnaire were included (total sample, 1161; derivation cohort, 344; external validation cohort, 817). A two-predictor logistic regression model was developed at the coordinating center and validated at the remaining centers. Bootstrap-adjusted discrimination and calibration were assessed. A categorical version of the model was converted into an integer scorecard (0-11 points) with decision-curve-derived triage zones.ResultsThe area under the receiver operating characteristic curve was 0.899 (95% confidence interval 0.863-0.935) in derivation and 0.866 (0.837-0.895) in external validation. Calibration in the validation cohort showed systematic overestimation (expected-to-observed ratio 1.85); after intercept recalibration, the Brier score decreased from 0.14 to 0.11. Decision curve analysis showed net benefit across threshold probabilities 0.10-0.50. In validation, the Green zone (score ≤2) included 313 participants (38.3%) with a negative predictive value of 0.98; the Yellow zone (score 3-4) included 180 (22.0%); and the Red zone (score ≥5) included 324 (39.7%) with a positive predictive value of 0.45. Monthly acute medication days accounted for most of the discriminative performance; the treatment-optimization component provided additional stratification, particularly in the intermediate medication-use range (4-14 days/month).ConclusionThe Migraine Analgesic Usage Index offers a concise, externally validated triage aid for identifying high multidimensional migraine burden as defined by the four-domain composite. It may help prioritize comprehensive assessment but does not replace clinical evaluation. Prospective studies should test whether index-guided triage improves decision quality and patient outcomes.Trial registrationChinese Clinical Trial Registry, https://www.chictr.org.cn/, ChiCTR2400083678.

Для цитирования: Li Hui, Xu Xiaonuo, Che Linyi, Fan Xiaoping, Tan Ge, Ma Jingxi, Pan Qi, Hong Peiwei, Zhong Chengqing, Li Jiao, Chen Xiaorong, Dong Liang, Zhou Jiying. Development and external validation of a migraine analgesic usage (MAU) index for identifying high-severity migraine: A multi-center study.. Cephalalgia : an international journal of headache. 2026. DOI: 10.1177/03331024261478621.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.